Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Non-Current Liabilities: 2022-2025

Historic Other Non-Current Liabilities for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $1.9 million.

  • Stoke Therapeutics' Other Non-Current Liabilities fell 38.56% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 38.56%. This contributed to the annual value of $2.5 million for FY2024, which is 49.26% down from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Other Non-Current Liabilities is $1.9 million, which was up 49.32% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Other Non-Current Liabilities ranged from a high of $4.9 million in Q4 2023 and a low of $959,000 during Q3 2023.
  • Over the past 3 years, Stoke Therapeutics' median Other Non-Current Liabilities value was $2.3 million (recorded in 2023), while the average stood at $2.6 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 73.43% in 2023, then soared by 218.04% in 2024.
  • Over the past 4 years, Stoke Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $3.0 million in 2022, then skyrocketed by 64.56% to $4.9 million in 2023, then tumbled by 49.26% to $2.5 million in 2024, then tumbled by 38.56% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.3 million for Q2 2025, and $1.9 million during Q1 2025.